Major Europe-based consumer health players GSK, Sanofi, Bayer and Reckitt feature in this earnings preview, which highlights what to look out for as these four firms report their Q4 and annual results over the coming weeks.
GSK’s full year financial performance will likely play second fiddle to the potential sale of its Consumer Healthcare business when it reports 2021 sales on 9 February.
Join thousands of industry professionals who rely on HBW Insight for daily insights
Already a subscriber?
C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.
Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.
US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.
Concern is unavoidable for most marketers of OTC drugs and dietary supplements in the US. As Canaccord Genuity analysts said in a 15 April research note, “uncertainty remains about how the tariff situation will play out.”
NAD and NARB track their decisions on support for ad claims with Federal Trade Commission policies, including the requirement of RCTs to support health claims for supplements, a standard the industry argues is required for drug claims and shouldn’t be applied for dietary ingredients.
CHPA Health In Hand Foundation accepting nominations for 2025 US Self-Care Marketing Awards; Celsius hires former PepsiCo as president/COO and closes $1.8bn acquisition of energy drink competitor Alani; and AdvoCare adds John Peirano as integrated marketing VP after hiring Kathy Blosser supply chain VP.
Swedish producer of antioxidant astaxanthin AstaReal has expanded its product offering with cardiovascular health focused-brand Kyolic.
